IMCR Q1 2025 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$94M+33.2% YoY

Gross Profit

$93M99.1% margin

Operating Income

-$4M-3.9% margin

Net Income

$5M5.4% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

$435,000

Free Cash Flow

$137,000

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$650M

Stockholders' Equity

$378M

Cash & Equivalents

$477M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$94M	$71M	+33.2%
Gross Profit	$93M	$70M	+32.4%
Operating Income	-$4M	-$26M	+86.3%
Net Income	$5M	-$24M	+120.6%

Revenue Segments

Sale of Therapies

$94M100%

Geographic Segments

UNITED STATES

$57M60%

Europe

$33M35%

International

$4M5%